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ABSTRACT 
INTRODUCTION 
Enterobacteriaceae  are inhabitants of human, animal gastrointestinal tract and 
various other environmental sites.Escherichia coli and klebsiella pneumoniae 
initially responded to betalactam antibiotics but there was an increase in 
resistance to betalactam antibiotics due to beta lactamase produced by them. 
Resistance to carbapenems has now become more prevalent due to production 
of carbapenemases. NDM-1 is a novel metallo betalactamase that is capable of 
hydrolysing all beta lactam antibiotics except Aztreonam. 
AIM 
Molecular detection of NDM-1 in Escherichia coli and klebsiella 
pneumoniae,Comparison of phenotypic methods of identifying carbapenemases 
and Screening of carbapenamases colonising in rectal samples of I.C.U  
Patients. 
MATERIALS AND METHODS 
After Ethical clearance 100 samples of carbapenem resistant Escherichia coli  
and klebsiella pneumoniae were randomly selected and  phenotypically 
compared by Double disc synergy test,combined disc test,Modified Hodge test 
and Carba Np test.Molecular detection and sequencing of NDM-1was 
done.Screening for  carbapenemases in Rectal swab of I.C.U patients were 
done using Carba chrome plate. 
 
 
RESULTS 
A total of 100 samples of Escherichia coli (42%) and klebsiella 
pneumoniae(58%) were selected. On comparison of  phenotypic methods  like 
Double -disc synergy, combined disc test, Modified Hodge test and Carba Np 
test , we observed  Carba Np test was 100% sensitive and 100% specific. A 
total of 82% strains were found to be NDM-1 positive yielding 475bp amplicon 
by molecular methods. Nine samples were sequenced  of which five were 
NDM-1, two were NDM-4, and remaining two were NDM-3,  and NDM-5. 
About 8% carriers were identified on Screening of rectal swabs of  50  patients  
in I.C.U  for carbapenemases 
CONCLUSION  
NDM-1 was detected in 82% 0f samples. Appropriate detection of 
emerging mechanism of resistance will prevent unnecessary mortality and 
morbidity. Carbapenamase carrier state was 8% and the less incidence is 
probably due to the infection control measures. 
Key words :NDM-1-Newdelhi metallobetalactamases;I.C.U  Intensive 
care unit 
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ENTEROBACTERIACEAE 
Enterobacteriaceae   are inhabitants of wide variety of niches, including 
the human, animal gastrointestinal tract and various other environmental sites. 
The family Enterobacteriaceae includes a large number and diversity of genera 
.The clinically important members of this family are considered in two groups 
namely opportunistic pathogens and intestinal pathogens. 
 Typhi and shigella spp are intestinal pathogens. The opportunistic 
pathogens are Citrobacter spp, Enterobacter spp, Klebsiella spp, Proteus spp, 
Serratia spp. Escherichia coli is a normal bowel inhabitant and is classified 
between the overt pathogens and opportunistic pathogen. Yersinia pestis is not 
an intestinal pathogen ,it causes plague
1
. 
Escherichia coli causes urinary tract infections, cystitis, bacteremia, 
neonatal meningitis, diarrhea and dysentery. Shigella causes acute 
inflammatory colitis and bloody diarrhea. Salmonella is associated with enteric 
fever .Yesinia causes plague.  
Other species like Klebsiella, Citrobacter, Enterobacter, Morganella, 
Providentia, proteus, serratia causes a wide variety of nosocomial infections of 
respiratory tract, urinary tract, and other normally sterile sites. They most 
frequently infect hospitalized and seriously debilitated patients.
 1 
Treatment of Escherichia coli infections depend on the site and severity 
of the infection. Intraabdominal abscesses caused by Escherichia coli are 
treated with Ampicillin.  Meningitis and pneumoniae are treated with third 
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generation cephalosporins like ceftriazone. Doxycycline, TMP/SMZ, 
fluroquinolones, Rifaximin are used in treatment of enteric infections 
.Uncomplicated cystitis requires TMP/SMZ and nitrofurantoin where as 
complicated cystitis responds to quinolones. 
Klebsiella infections are intrinsically resistant to Ampicillin, Ticarcillin 
and nitrofurantoin is poorly active against them. In Severely ill patients with 
Klebsiella infections, the treatment options include third generation 
cephalosporins, quinolones and amino glycosides
2
. 
Escherichia coli and klebsiella initially responded to betalactam 
antibiotics  there was a dramatic increase in resistance to betalactam antibiotics 
due to beta lactamases produced by them. These enzymes break the beta lactam 
ring, making them unable to bind to the penicillin binding proteins and 
terminate their activity
3
.But this resistance was superseded by use of second 
and third generation cephalosporins and combination of betalactam antibiotics 
with betalactamases inhibitors.  
With the emergence of ESBLs, carbapenems became the drug of choice. 
Resistance to carbapenems has now become more prevalent in 
Enterobacteriaceae due to production of carbapenamases. Dissemination of 
these pathogens is of great concern because there are only few antibiotics of 
choice for these resistant pathogens but none are orally available and are 
expensive
3
. Among the newly emerged beta lactamases, New Delhi Metallo 
betalactamases (NDM-1) represents a war between the bugs and drugs.NDM-1 
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producing organisms are called super bugs. This NDM-1 is a novel metallo 
betalactamases that is capable of hydrolysing all beta lactam antibiotics except 
Aztreonam
4
.
 
In 2009, NDM-1 was first reported in Klebsiella pneumoniae, which 
was isolated in a Swedish patient, who was treated in an hospital in New Delhi 
previously. His faecal sample collected during his stay in hospital carried E.coli 
also. The gene encoding NDM-1 is the blaNDM-1 gene. Although this gene was 
identified in different members of the family Enterobacteriaceae, E.coli and 
Klebsiella remain the most frequent NDM-1 producers throughout the world. 
They are considered as   significant  pathogens causing infections in the 
hospital settings and the community
5
.  
In view of the above facts, the present study is undertaken to detect the 
presence of New Delhi metallo betalactamases in Escherichia coli and 
Klebsiella in clinical isolates of a tertiary care hospital. 
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ENTEROBACTERIACEAE 
Gram negative bacteria belonging to the family of Enterobacteriaceae 
are the most frequently isolated organisms from clinical specimens. They are 
widely dispersed in soil, water, plants. As the name indicates it is also present 
in intestinal tract of human and animals. The members of this family of 
Enterobacteriaceae exhibit general morphological and biochemical similarities. 
Within the family they exhibit wide biochemical and antigenic heterogeneity. 
The members of the Enterobacteriaceae are considered into two groups 
the opportunistic pathogens and intestinal pathogens. Typhi and Shigella spp 
are in the latter group. The opportunistic pathogens are Citrobacter spp, 
Enterobacter spp, Klebsiella spp, Proteus spp, Serratia spp. Escherichia coli is 
a normal bowel inhabitant and its position is somewhere between the overt 
pathogen and the opportunistic pathogen. 
The members of Enterobacteriaceae family are incriminated in virtually 
any type of infectious diseases and recovered from any specimen received in 
the laboratory. Immunocopromised patients are highly susceptible to hospital 
acquired infections following invasive procedures like catheterization, 
bronchoscopy, colposcopy, surgical biopsies, in which mucous membrane are 
traumatized
1
.  
ESCHERICHIA COLI 
Escherichia coli was first named after Escherich , who first described the 
colon bacillus under the name Bacterium coli immune. E.coli is a gram 
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negative, straight rod measuring 1-3 micrometer, arranged singly or in pairs. It 
is motile by means of peritrichate flagella. Some strains are non motile
1
. E.coli 
is the one of the most common gram negative bacteria causing sepsis and 
endotoxic shock, urinary tract infections, meningitis in neonates and 
pneumonia in immunocompromised.The members of Escherichia have the 
following key reactions.   They are Gram negative rods , motile, catalase 
positive, Oxidase negative, lactose fermenters, indole positive; methyl red 
positive; Vogesproskauer negative; citrate and urease negative
6
. 
KLEBSIELLA PNEUMONIAE 
The genus klebsiella was named after Edwin kleb, a German 
microbiologist of nineteenth century
1
.They are non motile non capsulated rods 
that grow in ordinary media, forming dome shaped mucoid colonies of 
different degree of stickiness. They are short plump rods .The capsule is 
prominent and can be made out in gram stains as clear halo. Klebsiella exists as 
commensal in intestine and as saprophytes in  soil and water
.
.It is the well 
known cause of fatal pneumonia
6
.They are Gram negative  rods, catalase 
positive and Oxidase negative. They produce enormous amount of carbon 
dioxide,  so that the deep portions of KIA and TSI slants are pushed half way 
up the tube.They are lactose  fermenters  forming mucoid  colonies ;Indole  
positive ; citrate and urease positive ;Methyl red  negative ;voges proskauer 
positive.
6 
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TREATMENT   PROTOCOL   
The 20
th
 century saw a series of discoveries that has created remarkable 
changes in medical field. Among them, the most important is the discovery of 
anti microbial agents which began with synthesis of Arsphenamine by Paul 
Ehrlich for the treatment of syphilis.  Shortly after that optochin (ethyl cuprine) 
was tried for the treatment of pneumococcal pneumonia. This was then 
followed by sulphonamides, penicillin’s, antituberculous drugs and antifungal 
drugs in the middle of 20
th
century
7.
 
Due to the growing array of antibiotic resistance, the treatment protocol 
for Escherichia coli and Klebsiella pneumoniae must be based on 
Antimicrobial susceptibility testing, site of infection and the co morbid 
conditions. Intraabdominal abscesses caused by Escherichia coli are treated 
with Ampicillin.  Meningitis and pneumoniae are treated with third generation 
cephalosporins like ceftriazone. Doxycycline, TMP, TMP/SMZ, 
fluroquinolones, Rifaximin are used in treatment of enteric infections 
.Uncomplicated cystitis requires TMP/SMZ and nitrofurantoin where as 
complicated cystitis responds to ceftriazones and quinolones. Klebsiella 
infections are intrinsically resistant to Ampicillin, Ticarcillin .Nitrofurantoin is 
poorly active against them. In Severely ill patients with Klebsiella infections, 
the treatment options include third generation cephalosporins, quinolones and 
amino glycosides.
2
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MECHANISM OF RESISTANCE 
 Antibiotic resistance is increasing  both in community and hospital. 
Resistance to antibiotic among the bacteria is widely seen in day to day 
practice .Among them Gram negative bacteria has created a greater threat to 
human health
8
.Synthesis of betalactamases which are capable of hydrolysing 
betalactam,  target alteration,  efflux  mechanism  , alteration in metabolic 
activity are the main mechanisms of drug resistance
9
. 
 Gram negative bacterial infections resistant to various antibiotics were 
successfully treated in the past with penicillin group of antibiotics like 
piperacillin and other penicillin groups.. Carbapenems posses maximum 
antimicrobial activity. This feature  is due to high affinity towards penicillin 
binding protein 2,  being stable  against major serine based betalactamases and 
good  outer membrane permeability. Carbapenems are considered as one of the 
important drugs used in treatment of drug resistant gram negative pathogens. 
Inappropriate usage of carbapenems has resulted in development of resistance 
to carbapenems also.
   
During the past ten years the antibiotic resistance in 
Enterobacteriaceae has become a major concern
10
. 
Escherichia coli and klebsiella pneumonia causes a variety of 
nosocomial and community acquired infections
11
. It possesses betalactamases 
which mediates high level of resistance to betalactam antibiotics. It also has 
acquired resistance to cephalosporins through plasmids containing 
chromosomally encoded Amp c betalactamases
12
.
 
The wide spread use of 
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carbapenems which are the only drug active against these resistant bacteria 
resulted in emergence of a new antibiotic resistant mechanisms
13
. Resistance to 
carbapenems is predominately mediated by metallobetalactomases, a class B 
type of betalactamases that are capable of recognising bivalent metal ions
14
.
 
CLASSIFICATION OF BETALACTAMASES 
 
 
EXTENDED SPECTRUM BETALACTAMASES 
Emergence of resistance to betalactam antibiotics emerged even before 
the discovery of the first beta lactam penicillin. The first betalactamases was 
identified in Escherichia coli prior to the release of penicillin for medical 
practice
15
. The first plasmid mediated betalactamases in gram negative bacteria 
was TEM-1, which was originally isolated in a single strain of Escherichia coli, 
isolated from blood culture of a patient named Temonier in Greece
16
.  SHV-1 is 
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chromosomally mediated betalactamase in Klebsiella pneumonia and plasmid 
mediated  betalactamase in Escherichia coli
17
. 
A new family of plasmid mediated ESBL called CTX-M, which hydrolysed 
cefotaxime had arose and were classified in Ambler Class A and in 2be of 
Bush, Jacoby and Medeiros classifications. The serine residue present at 
position 237 in CTX-M plays an important role in the extended spectrum 
activity of the CTX-M type of betalactamases. The unique feature of this 
enzyme is being inhibited by betalactamases inhibitor Tazobactum
18. 
Next is the OXA ESBL, which confers resistance to Ampicillin and 
cephalothin. They are characterised by their high hydrolytic activity against 
oxacillin and are poorly inhibited by clavulanic acid
17
. Majority of OXA-type 
ESBLS confer resistance to ceftazidime; the OXA-17 betalactamases confers 
resistance to cefotaxime and ceftriaxone but only marginal protection against 
ceftazidime
19.
 
Some uncommon ESBLs are found in Pseudomonas aeruginosa. They are 
PER-1 in isolates in Turkey, France and Italy; VEB-1, VEB-2 strains from 
South East Asia; GES-1, GES-2, IBC-2 isolates from South Africa, France and 
Greece
20
. PER-1 is also reported in multidrug resistant Acinetobacter species. 
Some of these enzymes are found in other Enterobacteriaceae as well
21
.There 
are some uncommon ESBLs found only in Enterobacteriaceae, they are BES-1, 
IBC-1, SFO-1 and TLA-1
22
. 
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DETECTION OF ESBLS  
As per CLSI 2014 initial screening and confirmatory tests for production 
of ESBL in Escherichia coli and Klebsiella pneumoniae is done using disc 
diffusion and Broth micro dilution methods. 
Initial screening test is done by disc diffusion on MHA with the following discs 
TABLE-1 
 
 
Zones above may indicate ESBL production. The use of more than one 
antimicrobial agent for screening improves the sensitivity of ESBL detection. 
In Broth micro dilution, the growth at or above the screening 
concentrations indicate ESBL production i.e. MIC ≥8ug/ml for Cefpodoxime, 
MIC ≥2ug/ml for Ceftazidime, Aztreonam, Cefotaxime and Ceftriaxone. 
 Phenotypic confirmation of the ESBL producing stains by disc 
diffusion is performed by testing both cefotaxime30ug and ceftazidime30ug 
alone  and  in combination with clavulanate 10ug.A ≥ 5mm increase in zone 
diameter for either antimicrobial agent tested in combination with clavulanate 
Drug sensitivity disc Sensitivity zones 
Cefpodoxime  ≤ 17mm 
Ceftazidime ≤ 22mm 
Aztreonam ≤ 27mm 
Cefotaxime ≤27mm 
Ceftriaxone ≤ 25mm 
13 
 
versus the zone diameter of the agent when tested alone is confirmatory of 
ESBL. In Broth microdilution method a ≥3 twofold concentration decrease in 
an MIC for Cefotaxime (0.25-64ug/ml) or Ceftazidime (0.25-128ug/ml) in 
combination with clavulanate versus the MIC of the antimicrobial agents when 
tested alone is confirmatory for ESBL production. 
CARBAPENAMASES 
The carbapenam antibiotic obtained from Thienamycin was produced by 
the soil organism streptomyces cattleya
23
. As these molecules were present in 
soil , it is a logic to expect that  the organisms  present in soil to produce some 
enzymes (carbapenamases) capable of degrading the betalactam molecules, 
produced by streptomyces cattleya for their survival
24
. In addition these 
chromosomal carbapenamases might have evolved initially as a mode of 
protection of bacterial cell wall against external dangers
25
. 
Carbapenems are the antimicrobials used as a last resort for the 
treatment of infections caused by ESBL or Plasmid mediated AmpC producing 
organisms. They are also resistant to other group of Antibiotics like 
Quinolones, Amino glycosides and cotrimoxazole
26. 
Carbapenamases are 
heterogeneous mixture of betalactamases belonging to molecular Ambler Class 
A, Class B (Metallo betalactamases) and Class D (Oxacillinases).They have a 
common property of hydrolysing  Imipenam, Meropenam together with other 
penicillin or cephalosporin Antibiotics
27
. 
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Metallo betalactamases are the betalactamases with the ability to 
hydrolyse carbapenems and are resistant to commercially available betalactam 
inhibitors but susceptible to inhibition by metal ion chelators. These enzymes 
hydrolyse cephalosporins and penicillin’s but lack the ability to hydrolyse 
Aztreonam
28
.                                              
The class B enzymes are plasmid mediated and integron located. It 
includes IMP-( active on imipenem),VIM-(Verona integron encoded 
Metallobetalactamase) ,GIM-(German imipenemase) ,SPM-1(Sao Paul 
imipenemase), SIM-1 (Seoul imipenemase) ,NDM-(New Delhi 
metallobetalactamases). 
The metallobeta lactamases are sub classified into three subclasses 
based on their structural features, zinc affinities for the two binding sites and 
hydrolysis. 
The sub classes B1 and B3 bind with two zinc ions to achieve maximal 
hydrolysis. But the enzymes in B2 subclass are inhibited if a second zinc ion is 
added to it. The enzymes of B2 subclass hydrolyses only the carbapenems in 
contrast to the broad spectrum hydrolysis exhibited by the B1 and B3 
enzymes
29
.  
NEWDELHI METALLOBETALACTAMASES 
Our target of interest NDM was first discovered in patients who had a 
history of travel to Indian subcontinent and hence named as New 
Delhimetallobetalactamase.NDM was isolated first in 2009 in a single isolate 
15 
 
of Klebsiella pneumonia, which were first recovered from a patient who 
returned back to Sweden after being treated in a hospital in New Delhi
 
.During 
his stay in hospital his faecal sample also was positive for NDM-1 producing 
E.coli
30
.  
NDM hydrolyses all beta lactam antibiotics except Aztreonam and are 
susceptible to colistin and less consistently to Tigecycline
5
. The NDM 
producers has several factors which are alarming the public health.  Firstly, the 
bla NDM gene which is identified in NDM is not present in a single species 
alone but presents in many unrelated species indicating that this gene is 
spreading in a very rapid rate. Secondly, it is not only present in   Klebsiella 
pneumonia which is a nosocomial pathogen but also in Escherichia coli which 
is a community acquired pathogen. Thirdly Escherichia coli is the number one 
cause of diarrhoea in children in India and Pakistan and thus with an increased 
risk of releasing the resistant strains into the environment. The lack  of 
sanitation facilities, unavailability of clean water,  Temperate climate and 
finally over population are the factors that contribute to the spread of NDM in 
India and Pakistan and then internationally
31
. The Indian continent, the Balkan 
regions, and the Middle East were found to be the main reservoirs producing 
New Delhi Metallobetalactamase. 
 The presence of NDM producers in the patients who were hospitalised 
in United Kingdom were found to been previously treated and hospitalised in 
Indian subcontinent. The same observation was noted in France, Italy and 
Sultanate of Oman
32
.  
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NDM-1 displays tighter binding to most of cephalosporins in particular 
to cefuroxime.NDM-1 at its active site has two metal ion binding sites: His and 
Cys sites. A 3D modelling of NDM-1 showed that two Zn ions were found at 
both of these His and Cys sites at a distance of 4.20 A
33
. On comparing IMP-1, 
VIM-2 and NDM-1 by an in silico  approach it was found that NDM-1 might 
have greater drug profile and catalytic efficacy than IMP-1 and VIM-2  due to a 
larger pocket opening and a lower distance between zinc-1 ion and beta lactam 
oxygen of the  carbapenam
34
. 
NDM-1 producers were mainly described in Urinary tract infections, 
peritonitis, septicaemia, pulmonary, soft tissue and device associated 
infections. In Enterobacteriaceae bla NDM-1 gene is located mostly   on 
conjugative plasmids
32
. 
Emigration and migration of population is considered as main factor in 
spreading of antibiotic resistance of organisms and their globalisation. The 
evolving drug resistance among Enterobacteriaceae is mainly due the genes 
located on the plasmids, which spreads to different bacterial species through 
genetic recombination
8
. 
The genes that code for NDM-1 producing organisms are located on 
different positions of plasmids (a180kb plasmid for klebsiella pneumonia and 
140 kb for Escherichia coli) 
5
. Lateral gene transfer has lead to the rapid 
dissemination and spread of resistance among different bacterial species
35
. 
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            It was reported in a study that all patients who are positive for NDM-1 
did not have a history of hospital admission in India
31
. 
 The symptoms produced due to infection caused by NDM-1 producing 
bacteria depend on the site of infection. Blood, urinary tract, lungs and wounds 
are the common site of infection
34
.  
Only two classes of drugs like polymyxin (colistin) and glycylcyclines 
(tigecycline) showed good in vitro activity against NDM-1 producers. 
Successful treatment of pan resistant Enterobacteriaceae with combination 
therapy of colistin and tigecycline has been reported in similar studies. 
Combinations using Aztreonam or any other monobactum which are resistant 
to hydrolysis by metallolactamases are recommended in some studies.  NDM-1 
containing bacterial strain may also have other mechanism of resistance like 
ampC or ESBLs which may hydrolyze the Aztreonam. So inhibitors of these 
enzymes (like NXL104) should be the part of combination therapy. 
Fosfomycin is suggested for use in carbapenemase producing pan resistant 
Enterobacteriacea
36
. 
DNA mutations resulting in changes in the amino acid sequence of the 
carbapenemase have produced in an ever increasing range of subtypes or 
variants of each of type of carbapenemase. 
Fifteen variants of NDM-1 have been identified. These variants were 
identified after sequencing and blasting. They differed from NDM-1 by various 
amino acid substitutions. 
18 
 
The first variant NDM-2 has been identified to have a C to G 
substitution at position 82 which resulted in substitution of a proline to an 
alanine residue at position 28. MIC values of Betalactams and carbapenems 
showed no difference between NDM-1 and NDM-2 producers.  
NDM-2 has been identified in several Acinetobacter baumanii strains 
but not in Enterobacteriaceae. NDM-3 was described which differed from 
NDM-1 by a single nucleotide change at position 95 (Asp-Asn) this change did 
not modify the hydrolytic activities of the enzyme
37
.  
NDM-4 Varies by a  amino acid alteration at position 154 (Met-Leu). 
But this amino acid substitution is responsible for increased hydrolytic activity 
of NDM-4 compared to NDM-1 towards Cefalothin, Ceftazidime, Imipenem, 
Meropenem but cefepime was less hydrolysed
38
. 
NDM-5 has substitution at position 154 (Met-Leu) similar to NDM-4 
conferring maximum hydrolytic activity against carbapenems ,further has a 
second amino acid substitution at position 88 (Val-Leu)
 39
. 
NDM-6 retains its uniqueness  by a single amino acid substitution at 233 
(Ala-Val), with no obvious modified hydrolytic activity of the enzyme
40.
 
 In NDM-7, bla NDM-7 gene differs from NDM-1 by two substitutions 
at position 130 (Asp-Asn) and 154 (Met-Leu).The Amino acid substitution at 
154 increases the hydrolytic activity of the enzyme
41
. NDM-8 has amino acid 
substitutions at 130 (Asp-Gly) and 154 (Met-Leu) 
42
. NDM-9 has single amino 
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acid substitutions E to K at 152 position (Gene Bank accession number 
KC999080)
35
. 
The NDM-1 primers used are NDM Forward: 5'-
GGGCAGTCGCTTCCAACGGT and  
NDM Reverse: 5'- GTAGTGCTCAGTGTCGGCAT (Sigma-Aldrich, 
Bengaluru), Which amplified an internal fragment of 475 bp of bla NDM-1 
gene. The design of primers are based on the sequence of the bla NDM-1 gene in 
the GenBank database under accession no HQ171206
43
.
 
DETECTION METHODS OF CARBAPENAMASES 
 Different methods of detection are   
33,44,45,46 
1. Modified Hodge test 
 
2. Double disc synergy test 
 
3. Combined disc  or Disc enhancement test 
 4. Carba Np Test 
5. Remodified Hodge test 
6. E test 
 MODIFIED HODGE TEST 
  Escherichia coli ATCC 25922 was taken and made as a lawn culture in 
Muller Hinton Plate and dried , 3-5 colonies of the test organism grown 
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overnight on a blood agar plate was picked and inoculated from the edges of 
the Meropenam disc(placed in centre of plate) in the form of straight line. After 
overnight incubation there was evidence of Enhanced growth around the test. 
Enhanced growth was positive for Carbapenamases production resulting in 
Clover Leaf Pattern. 
DOUBLE DISC SYNERGY TEST 
With the test colonies a lawn culture was made on MHA plate. A 6mm 
Whatmann No filter paper disc with 10ul of EDTA was placed in the centre of 
the disc. Merapemem 10ug and ceftazidime 30ug discs were placed on either 
side  at a distance of 10mm . On Incubation at 35
0
c   for 18-24hrs, any 
distortion or  indentation towards the disc  was considered  as positive. 
COMBINED DISC TEST 
The test colonies were incubated and a lawn culture was made on MHA, 
two Meropenem (10ug) and two ceftazidime (30ug) discs were placed on it. 
Nearly 10ul of EDTA was added to one of each Meropenem and ceftazidime 
discs . The plates were placed at 35
0
c for 24hrs.The zone size of greater than 
5mm was considered  as positive for metallobetalactamase  production. 
CARBA NP TEST 
One calibrated loop of test organism was taken from a MHA plate .The 
colony was suspended in Tris Hcl lysis buffer 20mmol/L, vortexed for 
1minute, incubated at room temperature for 30 minutes and centrifuged at 
21 
 
10,000 rpm for 5minutes. 30 ul of supernatant of centrifuged bacterial isolate 
was added to 100ul of a 1ml solution made of 3mg merapenem monohydrate, 
pH7.8, phenol red solution and 0.1mmol/l Znso4 and Incubated at 37
0
c for 2 
hrs. The colour of wells changed from Red to yellow in all the test strains 
producing carbapenemases. The colour remained red for the negative strains. 
REMODIFIED HODGE TEST
 
The ATCC Escherichia coli were inoculated in similar manner as the 
MHT.  Ertapenem discs are placed far enough so that their inhibition zones do 
not overlap. One of the discs is labelled Zn and to which 140 ug of Znso4 was 
added, the other disc was left blank. Two test isolates were streaked from both 
the merapenem discs to the periphery as mirror images. The plates were 
incubated at 35
0
c for 18-24 hrs and read. In MBL production indentation was 
seen with MHT with merapenem disc only
47.
 
E TEST 
E test strip is a double-sided strip consisting of Meropenem (4 to 256 
μg/ml) on one side and Meropenem plus EDTA (1 to 64 μg/ml) on the other. 
The E-test was placed on the  lawn culture of test organism. The presence of 
MBL was indicated by a reduction of MRP MIC ≥3 twofold dilutions in the 
presence of EDTA (ratio of MRP/MRP+EDTA of ≥ 8) or the appearance of 
phantom zones, or deformation of ellipses
48
. 
Klebsiella pneumonia and Escherichia coli were the most commonly 
reported bacteria producing New Delhimetallobetalactamases-1 enzyme. A 
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number of countries including the United Kingdom, Italy and Oman have 
several case reports of infections caused by NDM-1.  About 86.3% of these 
infections were from patients who had connection with the Indian subcontinent 
or Balkan countries
49.
 
In a study conducted in a tertiary care hospital in North East India out of 
270 isolates of Escherichia coli, fourteen were screened for carbapenamase 
production on basis of their reduction in susceptibility to Meropenam and 
Ertapenam. All the fourteen were found positive for blaNDM-1
50
.In a study 
conducted on the prevalence of NDM-1 in multidrug resistant 
Enterobacteriaceae in India, Pakistan and UK in 2010. NDM-1 producing 
Escherichia coli and Klebsiella were isolated from Forty four cases in 
chennai33. In a study conducted in a tertiary care hospital Bangalore, out of a 
total of seventy four multidrug resistant Gram negative bacilli isolates, thirty 
four were positive for bla NDM-1 gene
51
. 
In a survey conducted  among twenty four European countries  to gather 
information about the spread of NDM-1 producing Enterobacteriaceae ,a total 
of seventy four cases were reported  from thirteen countries from 2008-2010. 
these  fifty five cases were recorded with travel history and thirty one with  
history of admission in India or Pakistan and five with previous history of 
being  admitted in Balkan countries
52
. 
 In a study conducted in NDM-1 producing isolates of Klebsiella 
pneumoniae in North East Asia, Out of 219 isolates, nineteen were screened for 
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carbapenamases production. Among them  57.89% were from urine 15.79% 
were from sputum 10.53% from blood and 15.79%
  
were from pus. All the  
above screening positive isolates were found contain plasmid mediated NDM-1 
gene by molecular methods
4
.In a study conducted among Escherichia coli and 
Klebsiella pneumoniae isolates in a tertiary care hospital in south India ,75%  
of Klebsiella pneumoniae isolates were bla NDM-1 positive and 66% of  
Escherichia coli  were bla NDM-1 positive.
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The following databasis is obtained from a review of Google maps on 
the world wide dissemination of New Delhi metallobetalactamases 
In Afghanistan  2 isolates of NDM were first described in 2011 ; In 
Bangladesh  17 isolates  were described in 2008 ; In Canada   18  cases were 
described in 2009-2010 ;In  China   16 isolates described in 2009-2012 ;In 
France  4 isolates in2011  ;In India from Assam, Bangalore, Chennai, 
Guwahati, Haryana, Kolkata, Mumbai, New Delhi, Pune, Varanasi 374 cases 
were isolated in 2006-2007;Iran  1  isolate in 2011; Israel Jerusalem,  10 
isolates in 2010 .In Japan  4  cases isolated  in  2010;  Kenya,  7 isolates from 
2007-2009 ;  
In South Korea  4  isolates were described in 2010 ;Spain , 1  case 
isolated in 2012 ; In  Sweden Stockholm 4 cases were described in 2011 ; 
Switzerland Geneva 3 isolates in 2009-2010 . Taiwan Taipei 1 case in 2011. 
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In Thailand 6  isolates were described 2010 ; In  Vietnam , 2 isolates 
were described in 2010 United Arab , 2 isolates in 2011 ;In  United Kingdom  
,in  10 cities 23 isolates  were described in the year 2011
41
.  
Isolation of patients who are carriers from non carriers is the key 
component in preventing spread of carbapenamases in hospitals. Culture results 
alone cannot be solely relied to detect the carriers. Hence active surveillance 
should be carried out. The sites of Carbapenamase resistant Enterobacteriaceae 
includes lower G.I.T, the oropharynx, skin and urine. The primary surveillance 
site advocated by the US centers for Disease control and Prevention and 
European Society of Clinical Microbiology and Infectious disease is the rectal 
swab or stool
54
.            
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                     Aim and Objectives 
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AIM OF THE STUDY 
  To isolate  carbapenam resistant Escherichia coli and klebsiella 
pneumoniae from  various clinical specimens of a tertiary care hospital. 
 Molecular detection of New Delhi metallobetalactamases in Escherichia 
coli and klebsiella pneumoniae. 
OBJECTIVES 
 To isolate the carbapenam resistant  Escherichia coli and klebsiella 
pneumoniae from various clinical specimens. 
 Comparison of phenotypic methods of identifying carbapenamases. 
 Molecular detection of New Delhi Metallobetalactamases in Escherichia 
coli and klebsiella pneumoniae in clinical isolates of a tertiary care hospital. 
 Screening of carbapenamases colonising in rectal samples of I.C.U  Patients 
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Materials and Methods 
28 
 
After Ethical clearance from the institution, the study was conducted 
between April 2014 - August 2015. Out of Two thousand and forty two 
samples of Escherichia coli and thousand hundred and ninety two samples of 
Klebsiella pneumoniae, Five hundred and sixty samples of Klebsiella 
pneumoniae (47%) and hundred and forty eight isolates of Escherichia coli 
(7%) were resistant to carbapenems. A total of 100 strains from inpatients and 
out patients were studied randomly. 
STUDY POPULATION / SAMPLING METHODS 
Random sampling   Method 
SAMPLE SIZE 
100 samples   were selected randomly. 
TYPE OF STUDY 
Observational study. 
INCLUSION CRITERIA 
Carbapenem resistant  Escherichia coli and Klebsiella pneumoniae 
EXCLUSION CRITERIA 
 Escherichia coli and Klebsiella pneumonia  sensitive to Carbapenam. 
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STUDY DESIGN: 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Isolation of Escherichia coli and Klebsiella pneumoniae from clinical 
samples 
                    Identification by phenotypic methods 
Carbapenem resistance detected by Kirby Bauer disc diffusion with 
Ertapenem & Meropenem and Vitek 2 automation and stokes method 
Comparison of different phenotypic methods for carbapenemase detection 
like Double disc synergy, Combined disc, MHT and CarbaNp test 
                        DNA Extraction 
            Polymerase chain reaction 
   DNA sequencing and Blasting 
forSUBTYPES 
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Collection of  Rectal swabs of I.C.U patients who were on prolonged (>15days) 
or repeated Hospitalisation 
 
Screening on CARBA CHROME AGAR to detect the presence of 
Carbapenamase producing Escherichia coli and Klebsiella pneumoniae 
 
ISOLATION OF ESCHERICHIA COLI AND KLEBSIELLA 
PNEUMONIAE 
 Gram staining of all the isolates of Escherichia coli and Klebsiella 
pneumoniae were performed. Gram negative rods were observed in the direct 
smear and the samples were streaked in the Blood agar, Mac conkey agar. 
Biochemical reactions like catalase, oxidase and IMViC were done. 
SCREENING    FOR   CARBAPENAMASES: 
 The isolates were screened for the production of Carbapenam resistance 
using Ertapenem 10ug and Merapenam 10ug by standard Kirby bauer disc 
diffusion procedure and by strokes method. 
 As per CLSI 2014 Ertapenem non susceptibility is the most sensitive 
indicator of Carbapenem resistance. The zone diameter of inhibition < than 19-
21mm for Ertapenem and < than 16-21mm for Merapenam indicates 
Carbapenemase production.  Merapenam and Ertapenem were also tested with 
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automated identification system (VITEK 2) which analyses the susceptibility 
pattern based on Minimal Inhibitory Concentration. 
COMPARISON OF DIFFERENT PHENOTYPIC METHODS FOR 
DETECTION OF CARBAPENEMASES 
44,45,46 
DOUBLE DISC SYNERGY TEST 
 
The colonies to be tested were inoculated in peptone water and 
incubated at 37
0
C for 2 hours to get turbidity matching to Mac Farland 0.5. A 
lawn culture was made in Muller Hinton plate using a sterile cotton swab. A 
6mm Whatmann No filter paper disc with 10ul of EDTA was placed in the 
center of the disc. Ertapenem 10ug and ceftazidime 30ug discs were placed 
10mm apart. Incubated at 35
0
c for 24hrs any distortion  or  indentation towards 
the disc with EDTA was considered as positive. 
COMBINED DISC TEST 
 
The test colonies were inoculated and incubated at 37
0
c for two hours to 
match the Mac Farland turbidity of 0.5.A lawn culture was made in which two 
Ertapenem (10ug) and ceftazidime (30ug) discs were kept.  About 10ul of 
EDTA was added to one of the discs. The plates were kept at 35
0
c for 
24hrs.The  change in diameter of greater than 5mm was considered   positive .  
MODIFIED HODGE TEST 
A 0.5 MacFarland standard suspension of Escherichia coli ATCC 25922 
was taken and made as a lawn culture in Muller Hinton Plate. Allowed to dry 
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for 3-10 minutes. The Ertapenem disc was placed on the plate. Using 10 ul 
loops 3-5 colonies of the test organism grown overnight on a blood agar plate 
were picked and inoculated from the edges of the disc in the form of straight 
line .It is Incubated at 35
0
c.After over night incubation there was evidence of 
Enhanced growth around the test .Enhanced growth with clover leaf pattern 
was considered as positive for Carbapenemase production. 
CARBA NP TEST
 
One calibrated loop of test organism was taken from a MHA plate .The 
colony was suspended in Tris Hcl lysis buffer 20mmol/L, vortexed for 1minute 
and incubated at room temperature for 30 minutes. 
This bacterial suspension was centrifuged at 10,000 rpm for 5minutes. 
100ul of a 1ml solution made of 3mg Merapenam monohydrate, pH7.8, phenol 
red solution and 0.1mmol/l Znso4 was prepared. 30 microliter supernatant of 
centrifuged bacterial isolate was added to 100ul of the above suspension in a 96 
welled microtiter plate. 
Incubated at 37
0
c for 2 hrs. The colour of wells changed from Red to 
yellow in all the test strains producing carbapenemases. The colour remained 
red for the negative strains. 
  
33 
 
MOLECULAR DETECTION OF CARBAPENAMASES 
EXTRACTION OF DNA  
The isolates were incubated overnight at 35
0
c in Luria broth .About 2-3 
ml of inoculum was used for DNA extraction. 
PREPARATION OF LURIA BROTH: 
The Luria broth has the following ingredients 
                1. Tryptone 1.0%    - 10g 
               2. Yeast extracts 0.5% -  5g 
               3. Nacl 0.5%              - 5g 
               4. Water                - 1000ml 
The DNA was extracted by boiling  method. The isolates which 
inoculated in Luria broth were centrifuged at 5000rpm for 10 minutes. After 
centrifugation the supernatant was discarded and the pellet was taken in a 
sterile eppendorph tube. 
 The pellets were resuspended in distilled water and kept in a water bath 
at 95
0
c for 20 minutes. It is then cooled and centrifuged at 5000 rpm for 10 
minutes. The supernatant is the extracted DNA and is stored at _20
0
c.
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POLYMERASE CHAIN REACTION 
 The extracted DNA was mixed with forward, reverse primers for NDM-
1, master mix and PCR water and amplified in step one AB applied Bio system 
Real time PCR. 
 PCR cycle consists of the following steps.
55
  
Initial denaturation: 94°C for 3 min,  
Denaturation   at  94°C for 30 s 
Annealing at  60°C for 25 s  30 cycles 
Extension at 72°C for 30 s,   
Final extension at 72°C for 3 min. 
The amplified products are stored at _20
0
c
43 
TRIS BORIC ACETATE BUFFER PREPARATION 
            Tris base _ 10.78 g 
            Boric acid_ 5.50 g 
            EDTA_ 3.72g 
           1000 ml of milli Q water 
This is a 10x solution. 
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To about 450 ml of Milli Q water, 50ml of above prepared Tris boric acetate 
buffer was added to obtain 1x solution. 
PREPARATION OF ETHIDIUM BROMIDE 
10 mg of Ethidium bromide powder was added to 1ml of sterile distilled 
water. 
GEL PREPARATION AND GEL ELECTROPHORESIS 
 Agarose of 0.75g was added to 80ml of 1x solution .The mixture was 
mixed completely and melted for 2minutes in oven. A gel electrophoresis 
trough which can hold 80ml of water and 15 well combs was selected. 
 The melted agarose gel was cooled and Ethidium bromide (10mg/ml) 
1ul was added to it. The mixture was poured in the trough and the agarose gel 
was allowed to set in after placing the comb. 
 The electrophoresis tank was taken and filled with buffer; the set 
agarose gel was kept in the tank after removing the comb. The amplified DNA 
of 5ul was added to 3ul of Methylene blue and pipetted into the well, with a 
positive and negative control. 
 The electrophoresis tank was connected to voltage meter. The current 
passed from cathode to anode.  The temperature was set at 98
o
c and observed 
after 45minutes.After 45 minutes the gel was removed from Electrophoretic 
trough and placed in a gel Doc. The images of the gel were captured by Gel 
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doc and viewed. The presence of the NDM-1 gene was confirmed by the 
formation of bands at 475bp and a 100bp ladder was used for this purpose. 
GENE SEQUENCING 
 The amplied products which were confirmed for the presence of NDM-1 
were sent for gene sequencing to Eurofins Genomics Bangalore. 
GENE BLASTING 
 The sequenced gene was blasted using BIO EDIT software and results 
were interpreted in the NCBI (National centre for Biotechnology Information) 
website. 
SCREENING FOR THE PRESENCE OF CARBAPENAMASES IN I.C.U 
PATIENTS 
 The Rectal swab of 50 I.C.U patients who were hospitalised for more 
than 15 days were collected and plated on the Carba chrome plate which was 
commercially available. The plates were incubated at 37
0
c for 18-24 hrs and 
observed for the presence of coloured colonies. Escherichia coli appeared 
purple coloured. Klebsiella pneumonia appeared green coloured
56. 
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Results 
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Out of 2042  samples of Escherichia coli and 1192 samples of Klebsiella 
pneumoniae reported from April 2014 to August 2015, Five hundred and sixty 
samples of Klebsiella pneumoniae (47%) and Hundred and forty eight  isolates 
of Escherichia coli  (7%) were resistant to carbapenems. 
Among them Forty two isolates of Escherichia coli and Fifty eight 
isolates of  Klebsiella pneumoniae which were  resistant to carbapenem were  
selected randomly for the study as shown in  figure 1. 
Cultural characteristics and Biochemical reactions of Escherichia coli 
and Klebsiella pneumoniae are shown in figures 2, 3, 4 and 5. Escherichia coli 
formed beta haemolytic colonies on blood agar and bright pink colonies on 
Mac conkey. The colonies were large, thick, greyish white, moist, smooth 
opaque or partially translucent. Escherichia coli were  Catalase positive; 
oxidase negative; Indole  and methyl red positive; citrate and Voges proskauer 
were negative;        (IMViC ++--). 
 Klebsiella pneumonia formed non haemolytic grey moist colonies on 
blood agar and large dome shaped lactose fermenting mucoid colonies of 
varying degrees of stickiness in Mac conkey. The following biochemical 
reactions were observed. Catalase positive; oxidase negative; Indole and 
methyl red negative; ferments Glucose, lactose, sucrose were fermented with 
gas; citrate and  Voges proskauer positive; (IMViC --++).  
 The isolates were taken from clinical samples like urine (msu and 
catheterized), tracheal aspirate, sputum, pleural fluid, BAL, Abdominal drain, 
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wound swab, wound tissues, CVP tip, peritoneal fluid, duodenal aspirate and 
Blood. They are shown in Figure 6. All the strains were reconfirmed as 
carbapenems resistant by strokes, Kirby bauer disc diffusion method and 
automatic broth dilution tests (Vitek-2) Figure-7and 8. All the strains were 
100% resistant to Ceftazidime, Cefperazonesulbactum, Cefepime, Aztreonam, 
Imepenem, Meropenam, Gentamicin & ciprofloxacin.About 32% of the strains 
were sensitive to Amikacin. Cotrimoxazole was sensitive in 5% of isolates.All 
the isolates were sensitive to Tigecycline and Colistin (100%) ,as shown in 
table 3.  
The following phenotypic tests were compared. 
1. Double disc synergy test  
2. Combined disc test               figure-9  
3. Modified Hodge test  figure-10 
4. Carba NP test         figure-11 
It was observed that 42%  were positive by Double disc diffusion test,75% 
were positive by Combination disc test ,90% were positive by Modified Hodge 
test and 98% were positive by Carba Np test. The sensitivity and specificity of 
Carba Np test is 100 % and is better than Modified Hodge test (sensitivity 91% 
specificity 100%), Combined disc test (sensitivity 92% and specificity 50%) 
and double disc synergy test (sensitivity 42% and specificity 50%) It is shown 
in table 2. 
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All the strains were subjected to Molecular detection of NDM-1 type 
carbapenamases after extracting the DNA by boiling method in water bath, 
shown in Figure 12. 
The DNA was amplified using ABI step one Real time PCR (figure 
13).The amplified samples were subjected to Gel electrophoresis (figure-14) 
and the bands were viewed using Gel doc (figure -15).A total of eighty two 
(82%) strains were found to be NDM-1 positive (475bp) (figure-17).Gel 
pattern of NDM-1 is depicted in the figure 16 .Thirty seven (88%) of 
Escherichia coli and Forty five  Klebsiella pneumoniae(77%) were NDM-1 
producers. Urine samples were the maximum   forty mid stream urine and four 
catheterized (53%). 
Nine samples of amplified DNA (25ul) were sent randomly for 
sequencing at Euro fin genomics India pvt Ltd in Bangalore. Among them four 
were Escherichia coli and five were Klebsiella pneumoniae 
The results send by the Eurofins Genomics   were subjected to gene 
blasting using the BIO EDIT software and the sequence results were 
interpreted in NCBI (National centre for Biotechnology and Information) web 
site and shown in table-4 and figure 18-26. 
.On interpretation it was found that  PCR-1, PCR-2, PCR-4, PCR-6 and 
8 had amino acid sequences of NDM-1 and PCR-3 was NDM-5 and PCR-5 
was NDM-3 and PCR-7 and PCR-9 were NDM-4  
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The PCR-3 (NDM-5)  showed  a point mutation variant differing from 
NDM-1  having  a  Met  to Leu   (M-L) substitution at 154  and  Val  to  Leu  
(V-L)substitution at 88. 
PCR-5 (NDM-3) showed a point mutation variant differing from NDM-
1 having substitution of Asp to Asn (D-N) at 95. 
PCR-7 and PCR-9 (NDM-4) differs from NDM-1 by a single amino 
acid substitution   (M-L ) at 154 (Met to Leu). 
The results of screening of carbapenamases producing Escherichia coli 
and Klebsiella pneumoniae using Carba chrome agar plate are shown in figure 
27, 28.Out of fifty isolates four (8%) were found to be carbapenemases 
producers, three were Klebsiella pneumoniae (75%) and one was Escherichia 
coli (25%). 
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ESCHERICHIA 
COLI  
42% 
KLEBSIELLA 
PNEUMONIAE 
58% 
FIGURE-1 Percentage distribution of bacterial isolates used in study 
 
 
 
 
 
 
FIGURE-2 Mucoid lactose fermenting colonies of Klebsiella pneumoniae  
in Mac conkey agar 
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FIGURE-3 Flat lactose fermenting colonies of Escherichia coli in Mac 
conkey agar 
 
FIGURE-4 Biochemical reactions of Escherichia coli 
 
L to R 1.Indole + ve 2.Methyl red test + ve, 3.Voges prausker test - ve, 
 4. Citrate test -ve.  
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FIGURE-5 Biochemical reactions of Klebsiella pneumoniae 
 
L to R 1.Indole – ve,  2.Methyl red test - ve, 3.Voges prausker test + ve, 
            4.Citrate test +-.  
FIGURE-6 Distribution of various samples used in the study 
 
FIGURE-7 Carbapenem resistance screening by Ertapenem using 
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 Kirby bauer disc diffusion  method 
 
 
 
 
 
 
 
FIGURE-8 Carbapenem resistance screening by Ertapenem using stokes 
method 
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FIGURE-9 Detection of carbapenamase by double disc synergy test   and 
combined disc test ( arrow indicating synergy) 
 
FIGURE-10 Detection of carbapenamase by Modified hodge test 
 
 
 
 
 
 
 
 
FIGURE-11 Detection of carbapenamase by Carba Np test 
Ertapenem 
Test strain 
ATCC  25922 
Escherichia coli  
Ertapenem 
Ertapenem 
with  EDTA 
Ertapenem 
EDTA 
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Positive- Yellow colour; Negative- Red colour 
 
FIGURE-12 
WATER BATH 
 
FIGURE-13 Real time pcr machine (ABI-step one) 
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FIGURE-14  Gel electrophoresis of amplified  DNA of NDM gene 
 
  
49 
 
FIGURE-15 Gel doc EZ imager  (Bio Rad , USA) 
 
FIGURE-16 Gel electrophoretic analysis of amplified NDM-1 gene 
products 
   
 
 
 
 
Ladder 
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LANE-1&2- Escherichia coli ( +ve for NDM-1); 
LANE 3&4 –Klebsiella pneumoniae(+ve for NDM-1) 
FIGURE-17 prevalence of NDM-1 carbapenamase in our study (82%) 
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FIGURE -18  DNA sequencing results of  amplified NDM-1 
carbapenamase gene from Klebsiella pneumoniae 
Isolate-1 
 
>0615_227_14_PCR_1 
AACGATTGGCCTTGCTGTCCTTGATCAGGCAGCCACCAAAAGCGATGTCG
GTGCCGTCGATCCCAACGGTGATATTGTCACTGGTGTGGCCGGGGCCGGG
GTAAAATACCTTGAGCGGGCCAAAGTTGGGCGCGGTTGCTGGTTCGACCC
AGCCATTGGCGGCGAAAGTCAGGCTGTGTTGCGCCGCAACCATCCCCTCT
TGCGGGGCAAGCTGGTTCGACAACGCATTGGCATAAGTCGCAATCCCCGC
CGCATGCAGCGCGTCCATACCGCCCATCTTGTCCTGATGCGCGTGAGTCAC
CACCGCCAGCGCGACCGGCAGGTTGATCTCCTGCTTGATCCAGTTGAGGA
TCTGGGCGGTCTGGTCATCGGTCCAGGCGGTATCGACCACCAGCACGCGG
CCGCCATCCCTGACGATC 
AMINOACID BLAST(aminoacid sequence of above product) 
>0615_227_14_PCR_1 
IVRDGGRVLVVDTAWTDDQTAQILNWIKQEINLPVALAVVTHAHQDKMGG
MDALHAAGIATYANALSNQLAPQEGMVAAQHSLTFAANGWVEPATAPNFG
PLKVFYPGPGHTSDNITVGIDGTDIAFGGCLIKDS 
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FIGURE-19  DNA sequencing results of  amplified NDM-1 
carbapenamase gene from Klebsiella pneumoniae 
Isolate-2 
  
>0615_227_14_PCR-2 
GGCTTGCTGTCCTTGATCAGGCAGCCACCAAAAGCGATGTCGGTGCCGTC
GATCCCAACGGTGATATTGTCACTGGTGTGGCCGGGGCCGGGGTAAAATA
CCTTGAGCGGGCCAAAGTTGGGCGCGGTTGCTGGTTCGACCCAGCCATTG
GCGGCGAAAGTCAGGCTGTGTTGCGCCGCAACCATCCCCTCTTGCGGGGC
AAGCTGGTTCGACAACGCATTGGCATAAGTCGCAATCCCCGCCGCATGCA
GCGCGTCCATACCGCCCATCTTGTCCTGATGCGCGTGAGTCACCACCGCCA
GCGCGACCGGCAGGTTGATCTCCTGCTTGATCCAGTTGAGGATCTGGGCG
GTCTGGTCATCGGTCCAGGCGGTATCGACCACCAGCACGCGGCCG 
 
AMINOACID BLAST 
>0615_227_14_PCR_2 
GRVLVVDTAWTDDQTAQILNWIKQEINLPVALAVVTHAHQDKMGGMDALH
AAGIATYANALSNQLAPQEGMVAAQHSLTFAANGWVEPATAPNFGPLKVFY
PGPGHTSDNITVGIDGTDIAFGGCLIKDSK 
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FIGURE -20    DNA sequencing results of  amplified NDM-1 
carbapenamase gene from Klebsiella pneumoniae 
Isolate-3 
 
>0615_227_14_PCR-3 
TTTTGCTGTTGGTCGATACCGCCTGGACCGATGACCAGACCGCCCAGATCC
TCAACTGGATCAAGCAGGAGATCAACCTGCCGGTCGCGCTGGCGGTGGTG
ACTCACGCGCATCAGGACAAGATGGGCGGTATGGACGCGCTGCATGCGGC
GGGGATTGCGACTTATGCCAATGCGTTGTCGAACCAGCTTGCCCCGCAAG
AGGGGCTGGTTGCGGCGCAACACAGCCTGACTTTCGCCGCCAATGGCTGG
GTCGAACCAGCAACCGCGCCCAACTTTGGCCCGCTCAAGGTATTTTACCC
CGGCCCCGGCCACACCAGTGACAATATCACCGTTGGGATCGACGGCACCG
ACATCGCTTTTGGTGGCTGCCTGATCAAGGACAGCAAGGCC 
AMINOACID  BLAST 
>0615_227_14_PCR_3LLVDTAWTDDQTAQILNWIKQEINLPVALAVVTHAHQ
DKMGGMDALHAAGIATYANALSNQLAPQEGLVAAQHSLTFAANGWVEPAT
APNFGPLKVFYPGPGHTSDNITVGIDGTDIAFGGCLIKDSKA 
FIGURE-21 DNA sequencing results of  amplified NDM-1 carbapenamase 
gene from Klebsiella pneumoniae 
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Isolate-4  
 
>0615_227_14_PCR_4 
GGGGCAGTTTGGCTCCAACGGTTTGATCGTCAGGGATGGCGGCCGCGTGC
TGGTGGTCGATACCGCCTGGACCGATGACCAGACCGCCCAGATCCTCAAC
TGGATCAAGCAGGAGATCAACCTGCCGGTCGCGCTGGCGGTGGTGACTCA
CGCGCATCAGGACAAGATGGGCGGTATGGACGCGCTGCATGCGGCGGGG
ATTGCGACTTATGCCAATGCGTTGTCGAACCAGCTTGCCCCGCAAGAGGG
GATGGTTGCGGCGCAACACAGCCTGACTTTCGCCGCCAATGGCTGGGTCG
AACCAGCAACCGCGCCCAACTTTGGCCCGCTCAAGGTATTTTACCCCGGC
CCCGGCCACACCAGTGACAATATCACCGTTGGGATCGACGGCACCGACAT
CGCTTTTGGTGGCTGCCTGATCAAGGACA 
AMINOACID BLAST 
>0615_227_14_PCR_4GQFGSNGLIVRDGGRVLVVDTAWTDDQTAQILNWIKQ
EINLPVALAVVTHAHQDKMGGMDALHAAGIATYANALSNQLAPQEGMVAH
SLTFAANGWVEPATAPNFGPLKVFYPGPGHTSDNITVGIDGTDIAFGGCLIKD 
FIGURE-22  DNA sequencing results of  amplified NDM-1 
carbapenamase gene from Escherichia coli 
Isolate-5 
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>0615_227_14_PCR-5 
CTGGTGGTCGATACCGCCTGGACCAATGACCAGACCGCCCAGATCCTCAA
CTGGATCAAGCAGGAGATCAACCTGCCGGTCGCGCTGGCGGTGGTGACTC
ACGCGCATCAGGACAAGATGGGCGGTATGGACGCGCTGCATGCGGCGGG
GATTGCGACTTATGCCAATGCGTTGTCGAACCAGCTTGCCCCGCAAGAGG
GGATGGTTGCGGCGCAACACAGCCTGACTTTCGCCGCCAATGGCTGGGTC
GAACCAGCAACCGCGCCCAACTTTGGCCCGCTCAAGGTATTTTACCCCGG
CCCCGGCCACACCAGTGACAATATCACCGTTGGGATCGACGGCACCGACA
TCGCTTTTGGTGGCTGCCTGATCAAGGACAGC 
AMINOACID BLAST 
>0615_227_14_PCR_5 
LVVDTAWTNDQTAQILNWIKQEINLPVALAVVTHAHQDKMGGMDALHAAG
IATYANALSNQLAPQEGMVAAQHSLTFAANGWVEPATAPNFGPLKVFYPGP
GHTSDNITVGIDGTDIAFGGCLIKDS 
FIGURE-23 DNA sequencing results of  amplified NDM-1 carbapenamase 
gene from Klebsiella pneumoniae 
Isolate-6 
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>0615_227_14_SEQUENCE_6 
TTGCTGTCCTTGATCAGGCAGCCACCAAAAGCGATGTCGGTGCCGTCGAT
CCCAACGGTGATATTGTCACTGGTGTGGCCGGGGCCGGGGTAAAATACCT
TGAGCGGGCCAAAGTTGGGCGCGGTTGCTGGTTCGACCCAGCCATTGGCG
GCGAAAGTCAGGCTGTGTTGCGCCGCAACCATCCCCTCTTGCGGGGCAAG
CTGGTTCGACAACGCATTGGCATAAGTCGCAATCCCCGCCGCATGCAGCG
CGTCCATACCGCCCATCTTGTCCTGATGCGCGTGAGTCACCACCGCCAGCG
CGACCGGCAGGTTGATCTCCTGCTTGATCCAGTTGAGGATCTGGGCGGTCT
GGTCATCGGTCCAGGCG 
AMINOACID BLAST 
>0615_227_14_PCR_6 
AWTDDQTAQILNWIKQEINLPVALAVVTHAHQDKMGGMDALHAAGIATYA
NALSNQLAPQEGMVAAQHSLTFAANGWVEPATAPNFGPLKVFYPGPGHTSD
NITVGIDGTDIAFGGCLIKDSK 
FIGURE-24  DNA sequencing results of  amplified NDM-1 
carbapenamase gene from Escherichia coli 
Isolate-7 
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>0615_227_14_PCR-7 
GCGTGCTGGTGGTCGATACCGCCTGGACCGATGACCAGACCGCCCAGAT
CCTCAACTGGATCAAGCAGGAGATCAACCTGCCGGTCGCGCTGGCGGTGG
TGACTCACGCGCATCAGGACAAGATGGGCGGTATGGACGCGCTGCATGCG
GCGGGGATTGCGACTTATGCCAATGCGTTGTCGAACCAGCTTGCCCCGCA
AGAGGGGCTGGTTGCGGCGCAACACAGCCTGACTTTCGCCGCCAATGGCT
GGGTCGAACCAGCAACCGCGCCCAACTTTGGCCCGCTCAAGGTATTTTAC
CCCGGCCCCGGCCACACCAGTGACAATATCACCGTTGGGATCGACGGCAC
CGACATCGCTTTTGGTGGCTGCCTGATCAAGGACAGCAAGGCCA 
AMINOACID  BLAST 
>0615_227_14_PCR_6 
VLVVDTAWTDDQTAQILNWIKQEINLPVALAVVTHAHQDKMGGMDALHAA
GIATYANALSNQLAPQEGLVAAQHSLTFAANGWVEPATAPNFGPLKVFYPG
PGHTSDNITVGIDGTDIAFGGCLIKDSKA 
FIGURE-25  DNA sequencing results of  amplified NDM-1 
carbapenamase gene from Escherichia coli 
Isolate-8 
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>0615_227_008_PCR_8_NDMFwd 
GCGTGCTGGTGGTCGATACCGCCTGGACCGATGACCAGACCGCCCAGAT
CCTCAACTGGATCAAGCAGGAGATCAACCTGCCGGTCGCGCTGGCGGTGG
TGACTCACGCGCATCAGGACAAGATGGGCGGTATGAACGCGCTGCATGCG
GCGGGGATTGCGACTTATGCCAATGCGTTGTCGAACCAGCTTGCCCCGCA
AGAGGGGATGGTTGCGGCGCAACACAGCCTGACTTTCGCCGCCAATGGCT
GGGTCGAACCAGCAACCGCGCCCAACTTTGGCCCGCTCAAGGTATTTTAC
CCCGGCCCCGGCCACACCAGTGACAATATCACCGTTGGGATCGACGGCAC
CGACATCGCTTTTGGTGGCTGCCTGATCAA 
AMINOACID BLAST 
>0615_227_008_PCR_8_NDMFwd 
VLVVDTAWTDDQTAQILNWIKQEINLPVALAVVTHAHQDKMGGMNALHAA
GIATYANALSNQLAPQEGMVAAQHSLTFAANGWVEPATAPNFGPLKVFYPG
PGHTSDNITVGIDGTDIAFGGCLI 
FIGURE-26  DNA sequencing results of  amplified NDM-1 carbapenamase gene 
from Escherichia coli 
Isolate-9 
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>0615_227_009_PCR_9_NDMFwd 
GCGTGCTGGTGGTCGATACCGCCTGGACCGATGACCAGACCGCCCAGATC
CTCAACTGGATCAAGCAGGAGATCAACCTGCCGGTCGCGCTGGCGGTGGT
GACTCACGCGCATCAGGACAAGATGGGCGGTATGGACGCGCTGCATGCG
GCGGGGATTGCGACTTATGCCAATGCGTTGTCGAACCAGCTTGCCCCGCA
AGAGGGGCTGGTTGCGGCGCAACACAGCCTGACTTTCGCCGCCAATGGCT
GGGTCGAACCAGCAACCGCGCCCAACTTTGGCCCGCTCAAGGTATTTTAC
CCCGGCCCCGGCCA 
AMINOACID BLAST 
>0615_227_009_PCR_9_NDMFwd 
VLVVDTAWTDDQTAQILNWIKQEINLPVALAVVTHAHQDKMGGMDALHAA
GIATYANALSNQLAPQEGLVAAQHSLTFAANGWVEPATAPNFGPLKVFYPGP
G 
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FIGURE-27 Results of carrier rate of carbapenamase positive isolates 
from I.C.U patients 
 
FIGURE-28  carba chrome agar screening of faecal carriers of 
carbapenam resistant bacteria 
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TABLE- 2 Comparison of phenotypic methods 
S. 
NO 
NAME  OF 
THE TEST 
POSITIVES 
(%) 
NEGATIVES 
(%) 
SENSITIITY 
(%) 
SPECIFICITY 
(%) 
1 Double 
disc 
synergy  
test 
42 58 42 50 
2 Combined 
disc test 
75 25 92 50 
3 Modified 
hodge test 
90 10 91 100 
4 Carba NP 
test 
98 2 100 100 
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TABLE-3 Antibiotic susceptability pattern of carbapenam resistant 
bacteria  isolates(no:100) 
S.NO DRUG SENSITIVE (%) RESISTANCE (%) 
1 Ceftazidime Nil 100% 
2 Cefoperazone  sulbactum Nil 100% 
3 Cefepime Nil 100% 
4 Aztreonam Nil 100% 
5 Imipenem Nil 100% 
6 Meropenem Nil 100% 
7 Amikacin 32% 68% 
8 Gentamicin Nil 100% 
9 Ciprofloxacin Nil 100% 
10 Tigecycline 100% Nil 
11 Colistin 100% Nil 
12 Cotrimoxazole 5% 95% 
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TABLE-4 –DNA  sequencing results of NDM-1 carbapenamase genes 
studied  
ISOLATE AMINOACID SUBSTITUTION INTERPRETATION 
SEQ-I Aminoacid sequences of NDM-1 NDM-1 
SEQ-2 Aminoacid sequences of NDM-1 NDM-1 
SEQ-3 Met to Leu  (M-L) substitution at 154  
and  Val  to  Leu  (V-L)substitution at 
88. 
NDM-5 
SEQ-4 Aminoacid sequences of NDM-1 NDM-1 
SEQ-5 Substitution of Asp to Asn (D-N) at 95. NDM-3 
SEQ-6 Aminoacid sequences of NDM-1 NDM-1 
SEQ-7 Single amino acid substitution   (M-L ) 
at 154 (Met to Leu). 
NDM-4 
SEQ-8 Aminoacid sequences of NDM-1 NDM-1 
SEQ-9 Single amino acid substitution   (M-L ) 
at 54 (Met to Leu). 
NDM-4 
Isolate-1,2,3,4,6- Klebsiella pneumoniae 
Isolate-5,7,8,9-Escherichia coli 
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Discussion 
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Gram negative bacteria belonging to the family of Enterobacteriaceae 
are the most frequently isolated organisms from clinical specimens. They are 
incriminated in virtually any type of infectious diseases and recovered from 
any specimen received in the laboratory. 
 Escherichia coli and Klebsiella pneumoniae cause sepsis, endotoxic 
shock, urinary tract infections, meningitis in neonates and pneumonia in 
immune compromised .They are normally treated based on the antibiotic 
sensitivity, site of infection and co morbidity condition .Infections of 
Escherichia coli are treated with Ampicillin,  TMP/SMZ, doxycycline, 
cephalosporins and fluroquinolones. Uncomplicated cystitis requires 
TMP/SMZ and nitrofurantoin where as complicated cystitis responds to 
Ceftriaxones and quinolones. 
 Klebsiella infections are intrinsically resistant to Ampicillin and 
Ticarcillin. Nitrofurantoin is poorly active against them. In Severely ill patients 
with Klebsiella infections, the treatment options include third generation 
cephalosporins, quinolones and amino glycosides.
2
  
Escherichia coli and Klebsiella infections initially responded to 
betalactam antibiotics, but there was a dramatic increase in resistance to beta 
lactam antibiotics due to betalactamases produced by them. This resistance was 
superseded by use of second and third generation cephalosporins and 
combination of betalactam antibiotics with betalactamases inhibitors. 
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 Further with the emergence of ESBLs and Amp C resistance, 
carbapenems became the drug of choice.
3
There has been a rapid increase in 
carbapenems resistance in Enterobacteriaceae in the recent years. The 
carbapenems resistance may be due to carbapenamases production, Efflux 
pump and Amp C enzyme production with membrane impermeability. 
However, carbapenamase (betalactamases) were found to be the predominant 
mechanism of this resistance.
 
Ambler classified betalactamases as class A, class B, class D based on 
amino acid sequences. Carbapenamase resistance is associated with class A,B 
and class D. Class A and D contain betalactamases with serine in their active 
site; Class A hydrolyses all betalactams and is inhibited by clavulanic acid and 
Tazobactum. Class B also called as metallobetalactamases  hydrolyses all beta 
lactam except Aztreonam but are inhibited by EDTA. Class D enzymes 
hydrolyse carbapenems, weakly hydrolyse broad spectrum cephalosporins and 
are poorly inhibited by clavulanic acid and EDTA
57. 
These carbapenamases are classified under 2f and 3 groups in Bush 
jacoby and Medeiros
71
classification. The class B enzymes are plasmid 
mediated and integron located. It includes IMP-(active on Imepenam), VIM-
(Verona integron encoded metallobetalactamases), GIM-(German 
imipenemase), SPM-1 (Sao Paul imipenemase), SIM-1 (Seoul imipenamase), 
NDM- (New Delhi metallobetalactamase). But for NDM-1, others are rarely 
reported in Enterobacteriaceae.  
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 Among the newly emerged carbapenamases, New Delhi Metallo 
betalactamases (NDM-1) represents a war between the bugs and drugs.NDM-1 
producing organisms are called super bugs
4
. NDM-1 was first reported in 2009 
in Klebsiella pneumoniae and Escherichia coli. Both of them were recovered 
from a Swedish patient of Indian origin who was previously admitted in a 
hospital in New Delhi, India 
4
. Thereafter, NDM-1 has increasingly been 
reported from India and from several other parts of the world.  
Besides this, most of these NDM-1 positive bacteria are also resistant to 
a wide variety of Antimicrobials like aminoglycosides,flouroquinolones, 
macrolides and sulphonamides and carry several additional resistance 
mechanisms, leaving  only few or no therapeutic options
58
. 
In our study period carbapenem resistance was observed in 47% of 
Klebsiella pneumoniae and 7% of Escherichia coli in our hospital. 
 
  As per CLSI 2014 Ertapenem is a good marker for detection of 
Carbapenems resistance as others do not predict this resistance well. We 
randomly selected 42 Escherichia coli  followed by 58 klebsiella pneumoniae 
which were carbapenems resistant for molecular analysis. All these strains 
were resistant to Ceftazidime, Cefperazonesulbactum, Cefepime, Aztreonam, 
Imepenem, Meropenam,Gentamicin & ciprofloxacin but 32% were sensitive  to 
Amikacin  and 5%  were sensitive to cotrimoxazole . All of the above strains 
were susceptible to colistin and Tigecycline. 
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Most of Carbapenem resistant  strains  were from urine samples (47%). 
A similar study showed 57.89% carbapenamases producing Klebsiella 
pneumoniae in urine samples
4
. Khanduri et al detected in his study that among 
50 isolates of carbapenem resistant Enterobacteriaceae 44% were Klebsiella 
pneumoniae and 20% were Escherichia coli
74 
 The various methods of carbapenem resistance detection are double-disc 
synergy , Combined disc ,Modified Hodge  and Carba Np test. 
 Double disc synergy test was done with Ertapenem, ceftazidime and 
disc with EDTA in between .Any distortion of zone towards EDTA disc was 
considered positive. Combination disc test was done with Ertapenem   and 
Ertapenem with EDTA. An increase in zone diameter with combination disc of 
more than or equal to 5mm was considered as positive. Clover leaf pattern on 
the Muller hinton plate with in a lawn  ATCC Escherichia coli and test strain 
streaked perpendicular to it indicates positivity. Carba Np test was interpreted 
as positive if the test strain turns orange to yellow colour on incubation with 
carbapenems and phenol red as indicator. 
 Carba Np test is found to be the most specific and sensitive method to 
detect carbapenamases production. In our study also we found that Carba Np 
test is most specific (100%) and sensitive (100%) in detecting carbapenamases 
and it was better than Modified Hodge test ( sensitivity 91% specificity 
100%),Combination disc test (sensitivity 92% and specificity 50%) and Double 
disc synergy test (sensitivity 42% and specificity 50%). 
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In another study on comparison of   various phenotypic tests (DDST, 
CDT, MHT). Modified Hodge test was comparatively more specific and 
sensitive than Double disc synergy test and combination disc test
59
. Amjad et al 
observed carbapenamases in 69% of isolates (Escherichia coli, Klebsiella 
pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumanii, Citrobacter 
diversus, and Enterobacter agglomerans) by Modified Hodge test
60
. 
In a  study on comparison of carbapenemase detection   using a novel 
chromogenic rapid test—the Carba NP test and the modified Hodge test 
(MHT).Sensitivities were found to be comparable (CNP, 100%, versus MHT, 
98%; P  0.08), but Carba Np  was more specific (100% versus 80%; P < 
0.0001) and faster
61
.   
  In a similar study Carba NP test detected all carbapenemase producers 
regardless of the type of the carbapenemase and of their mucoid phenotype 
with 100% sensitivity and 100% specificity
62
. 
However molecular tests are the most accurate and usually taken as 
Gold standard. In our study we used the following primers to detect NDM-1 by 
conventional PCR 
NDM Forward: 5'-GGGCAGTCGCTTCCAACGGT and  
NDM Reverse: 5'- GTAGTGCTCAGTGTCGGCAT 
 
Amplification, sequencing and subsequent blasting were performed to 
identify the subtypes. Eighty-two (82%) strains were found to be NDM-1 
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positive (475bp) of which Thirty seven (45%) were Escherichia coli and Forty 
five were Klebsiella pneumoniae (54%). The presence of NDM-1 has also been 
reported in Bangladesh, Australia, Netherlands, USA, Canada, Japan, and 
China indicating that ―blaNDM-1is widely spread all over the world49. 
In a similar study from south India, NDM-1 was detected in 75%  of K. 
pneumoniae and 66% of E. coli by PCR and the remaining isolates were 
assumed to posses other mechanisms of resistance like efflux pumps, other 
carbapenamases, Amp C production and membrane impermeability
53. 
Fomda et al in his study conducted in Jammu and Kashmir observed that 
out of 15 class B metallobetalactamase producers, nine carried bla NDM-1 
gene of which 2 were Escherichia coli and 2 were Klebsiell
63
.
 
 DNA and protein sequencing were started in the 1970s, when the virus 
Lambda (50,000 nucleotides) was sequenced by Sanger et al.DNA sequencing 
was initially carried out for small genomes such as viruses and organelles, and 
complete sequencing of a bacterial genome were started later on with the 
improvements in sequencing technologies. Besides epidemiological 
surveillance sequencing has helped to identify new drug targets, which can be 
used in the design of novel antibiotics
74
. DNA mutations  has resulted in 
changes in the amino acid sequences and produced an ever increasing range of 
subtypes or variants in each of carbapenamase. 
Fifteen variants of NDM-1 have been identified. These variants were 
identified after sequencing and blasting. They differ  by various aminoacid 
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substitutions. NDM-4 was identified in Escherichia coli from a patient 
hospitalized in India, possessed a higher carbapenemase activity compared with 
NDM-1
43
. Ndm-4 producers were found in Africa specifically, in the highly 
populated city of Douala, which provided an environment that may promote the 
dissemination of this strains
64 
.In another study six NDM-4-producing E.coli 
isolates were obtained from two patients admitted to an Italian hospital
65
. 
NDM-5 was recovered from a Patient in the United Kingdom  
in  Escherichia coli  ST64  who had a  previous history of hospitalization in 
India
39
. 
NDM-7 was isolated from wound, throat and rectal swabs in a patient in 
Germany.
67
New Delhi metallo-β-lactamase-3 (NDM-3) was identified in a 
multidrug-resistant Escherichia coli isolate, obtained from the feces of a patient 
in Japan
68
. In another study NDM-5, NDM-6,NDM-7 were isolated in 
Enterobacteriaceae in India.The prevalence of NDM-5 to NDM-7 varients was 
significantly higher in Escherichia coli and particularly higher in urine 
samples.
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We found NDM-1 in 5 strains (56%),NDM-4 in 2 strains (22%) NDM-
3and NDM-5 in one strain each (11%).Colonization with potential pathogens is 
almost always an important cause for the development of nosocomial 
infections. But only a minority of colonized patients eventually develops 
clinical infection. It is influenced by various factors like pathogen virulence 
and host defence mechanisms, medical procedures, and exposure to antibiotics.  
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Identifying the risk factors for subsequent infections among colonized 
patients may promote control of modifiable risk factors and direct empirical 
antimicrobial therapy when necessary. A  SUPERCARBA medium with zinc 
,cloxacillin and a carbapenems molecule which detects carbapenemase 
producer (including OXA-48 producers) and other chrome  medium 
(CHROMagar KPC; CHROMagar, Paris) are used for screening 
carbapenemases
72
.
 
However, PCR for bla KPC represents the best screening test for KPCs 
in rectal swabs. It has significantly higher sensitivity and less hands-on time
73
.
 
 We found that carbapenems resistant carrier state was 8% in our study 
.Among them three were Klebsiella pneumoniae and one was Escherichia coli. 
A carrier state of 10-30% was reported from various studies in various parts of 
India and other countries
70
. The less incidence in this study is probably due to 
the infection control measures like effective decontamination of equipments, 
periodic assessment, routine hand hygiene   and  training  given to the medical 
and nursing staff. 
The spread of Enterobacteriaceae harbouring carbapenemases is a 
clinical and public health problem. Strict contact isolation and physical 
separation of carriers from non-carriers are key components in eliminating 
CRE in acute care hospitals. Sites of CRE carriage include the lower 
gastrointestinal tract, the oropharynx, skin and urine.  
73 
 
The primary surveillance screening site, which has been advocated by 
the US Center for Disease Control and Prevention CDC and the European 
Society of Clinical Microbiology and Infectious Diseases, is the stool or rectal 
swab
70
.
 
 Further characterization of the 18 strains (5 were Escherichia coli and 13 
Klebsiella pneumoniae which were negative for NDM-1 gene) for the 
mechanism of resistance was not done in our study. These isolates probably 
have other carbapenemases like VIM or it may have efflux changes or Amp C 
beta lactamase production with outer membrane impermeability.  
Presently NDM-1 producing bacterial infections can be managed with 
Colistin and Tigecycline combination. Colistin should not be given alone as it 
provokes resistance in vivo due to hetero resistant strains. Fosfomycin may also 
serve as an option for combination therapy against Multidrug resistant Gram 
negatives. Falagas et al observed by Meta analysis of 17 studies that 90% of 
NDM-1 positive isolates were susceptible to Fosfomycin. Detection of NDM-1 
like carbapenemases in members of Enterobacteriaceae will help in the 
management and prevention of spread of such bacteria in hospital and 
community which in turn will save the patients and valuable drugs. 
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Summary  
 
75 
 
 There has been a rapid increase in carbapenem resistance of particularly 
NDM-1 carbapenamase in Escherichia coli and klebsiella pneumoniae 
,the most common cause of bacterial infections .Present work  was 
under taken to study the NDM-1 carbapenamase resistance in bacteria  
 A total of Two thousand and forty two samples of Escherichia coli from 
same number of patients and thousand hundred and ninety two samples 
of Klebsiella pneumoniae from same number of patients were isolated 
between April 2014  and August 2015. 
 Carbapenems resistance was observed in five hundred and sixty samples 
of Klebsiella pneumoniae (47%) and hundred and forty eight isolates of 
Escherichia coli (7%) using Ertapenem and Meropenem susceptibility. 
  Forty two isolates of Escherichia coli and fifty eight isolates of 
Klebsiella pneumoniae were selected randomly from above 
carbapenems resistant strains for further characterisation. 
 Various phenotypic methods of detection of carbapenemases like 
Double -disc synergy, combined disc test, Modified Hodge test and 
Carba Np test done of which Carba Np test was 100% sensitive and 
100% specific. 
 Modified Hodge test was 91% sensitive and 100% specific; combined 
disc test was sensitive 92% and 50% specific; Double disc synergy test 
was 42% sensitive and 50%. 
 Molecular detection of NDM-1 type carbapenemases was done after 
extracting the DNA by boiling method in water bath. DNA was 
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amplified using ABI step -1 Real time PCR. The primers targeting 
NDM-1  were 
o NDM Forward: 5'-GGGCAGTCGCTTCCAACGGT and  
o NDM Reverse: 5'- GTAGTGCTCAGTGTCGGCAT 
 A total of eighty two (82%) strains were found to be NDM-1 positive 
yielding 475bp amplicon. 
 Nine samples of amplified DNA (positive for NDM-1) were sent for 
sequencing at Euro fin genomics India pvt Ltd in Bangalore.  
 The sequenced fragments were subjected to gene blasting using the BIO 
EDIT software and the sequence results were interpreted as per NCBI 
data base. Out of 9 samples, five were NDM-1, two were NDM-4, and 
remaining two were NDM-3,  and NDM-5. 
 Further characterization of the 18 strains (five were Escherichia coli and 
thirteen Klebsiella pneumoniae which were negative for NDM-1 gene) 
for the mechanism of resistance was not possible as a part of our study. 
These isolates probably had other carbapenemases or they may had 
efflux changes or Amp C beta lactamase production with outer 
membrane protein permeability. 
 Screening of  rectal swabs in 50 I.C.U patients  for carbapenemases 
producing Escherichia coli and Klebsiella pneumoniae  using Carba 
chrome agar plate identified 8% as carriers. Among them three were 
Klebsiella pneumoniae  and one was Escherichia coli . 
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Conclusion 
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Indiscriminate use of antibiotics led to the development of drug 
resistance to almost all antibiotics discovered. The latest among them is the 
development of carbapenams resistance through NDM-1 especially in the 
members of Enterobacteriaceae, which are the commonest etiological agents in 
various infections. Being a plasmid coded drug resistance it is spreading with 
enormous speed not only within the country but also in various nations across 
the globe. Appropriate detection of such emerging mechanism of resistance 
goes in a long way in preventing unnecessary mortality and morbidity among 
patients. 
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